

CURRICULUM VITAE

Joseph A. Chris Delaney, PhD

1. Biographical Information

Collaborative Health Studies Coordinating Center
Building 29, Suite 210
University of Washington,
Box 354922
6200 NE 74th Street
Seattle, WA 98115

Phone: (206) 897-1918
Cellphone: (206) 660-2915
FAX: (206) 616-4075
jacd@uw.edu

2. Education

McGill University, Montreal, Quebec, Canada, PhD, Epidemiology and Biostatistics, 2008
Lakehead University, Thunder Bay, Ontario, Canada, MA, Mathematics and Statistics, 1997
University of Western Ontario, London, Ontario, Canada, MSc, Physics, 1997
Lakehead University, Thunder Bay, Ontario, Canada, HBS, Physics, 1993
Lakehead University, Thunder Bay, Ontario, Canada, HBA, Philosophy, 1993

3. Licensure: not applicable

4. Professional Positions

Research Assistant Professor. Department of Epidemiology. University of Washington.
Seattle WA, USA. 2012/08 to present

Affiliate Assistant Professor. Department of Epidemiology. University of Florida, Gainesville,
FL, USA. 2011/07 to 2012/08

Assistant Professor. Department of Pharmaceutical Outcomes & Policy. University of Florida,
Gainesville, FL, USA. 2010/03 to 2012/08

Post-Doctoral Fellow. Department of Biostatistics. University of Washington, Seattle, USA.
2007/09 to 2010/03

Statistician. RASS Trial [Clinical trial run out of the University of Minnesota], Data Center,
Montreal, Quebec, Canada. 2003 to 2007/08

Statistician. Capital One Financial. Falls Church, Virginia, USA. 1998 to 2002

5. Honours, Awards, Scholarships

PDS Best Reviewer Recognition, 2014, 2013, 2012, 2010, 2008
 PDS Best Paper Award, 2010
 ICPE Student Conference Scholarship (entrance fees), 2007
 International Biometric Society, Best Student Paper, IBC XXIII, 2006
 ICPE Student Conference Scholarship (entrance fees), 2006
 CIHR Age Plus Prize (October 2004 Award of the month), 2004
 Lakehead University Entrance Scholarship, 1996
 NSERC Post-graduate Scholarship A, 1993-1995
 Canada Scholarship, 1989-1993

6. Professional Activities

Student Chair, International Society for Pharmacoepidemiology, 2006-2007

Member of editorial board, Pharmacoepidemiology and Drug Safety, June 2012-

Referee (pre-2014):

AHRQ White Paper (1 review)
 American Journal of Epidemiology (5 reviews)
 American Journal of Health-System Pharmacy (1 review)
 Annals of Internal Medicine (2 review)
 Archives of Internal Medicine (1 review)
 British Journal of Clinical Pharmacology (8 reviews)
 Bone (1 review)
 Canadian Medical Association Journal (10 reviews)
 DEcIDE for the AHRQ Effective Health Care Program (1 review)
 Diabetic Medicine (1 review)
 Epidemiology (2 reviews)
 Hindawi (1 review)
 Hypertension (1 review)
 JAMA Internal Medicine (1 review)
 Journal of Causal Inference (1 review)
 Journal of Clinical Epidemiology (3 reviews)
 Journal of Epidemiology and Community Health (7 reviews)
 Journal of Infectious Disease (1 review)
 Journal of the American Pharmacists Association (2 reviews)
 Journal of the American Society of Echocardiography (7 reviews)
 Journal of the American Statistical Association (2 reviews)
 Journal of the Royal Statistical Society (1 review)
 Journal of Women's Health (1 review)
 Open Medicine (2 review)
 Pharmacoepidemiology and Drug Safety (24 reviews)
 Pharmacotherapy (1 review)
 Value in Medicine (2 review)

2014/2015

American Journal of Preventative Medicine (1 review)
 BMC Public Health (1 review)
 Circulation (1 review)
 Journal of the American Heart Association (1 review)
 Journal of the American Society of Echocardiography (1 review)
 Pharmacoepidemiology and Drug Safety (7 reviews)

2015/2016

American Journal of Epidemiology (1 review)
 Journal of the American Heart Association (1 review)
 Journal of the American Society of Echocardiography (2 reviews)
 Pharmacoepidemiology and Drug Safety (7 reviews)

Reviewed Grant Applications for:

The Netherlands Organisation for Health Research and Development (1)
 Wellcome Trust (3)
 ZonMw's 'Rational Pharmacotherapy' program (1)
 UK Medical Research Council Methodology Research Panel (2)

Working Group Activities (major or leading role)

CHS Health Outcomes Working Group	2012 to present
STTR Substance Use Working Group	2014 to present
STTR HIV Medication Adherence Working Group	2014 to present
STTR Publications and Presentation Review Committee	2015 to present

Member of Society for Epidemiologic Research (SER) and the International Society for Pharmacoepidemiology (ISPE)

7. Bibliography**a) Refereed Research Articles**

1. Etminan M, Hemmelgarn B, **Delaney JA**, Suissa S. Lithium use and the risk of injurious motor vehicle crashes in older adults: A case control study. *BMJ* 2004; **328(7439)**:558-559.
2. Etminan M, Carleton B, **Delaney JA**, Padwal R. Antibiotic therapy for *Chlamydia Pneumoniae* in the secondary prevention of coronary artery disease: A meta-analysis of randomized trials. *Pharmacotherapy* 2004; **24(3)**:338-343.
3. Dial S, **Delaney JA**, Barkun A, Suissa S. The use of gastric acid suppressive agents and the risk of community-acquired *Clostridium difficile* associated disease. *JAMA* 2005; **294**:2989-2995.

4. Suissa S, Giroux M, Gervais M, Proulx P, Desbiens C, **Delaney JA**, Quail J, Stevens B, Nikolaj S. Assessing a Whiplash Management Model: A Population-Based Non-Randomized Intervention Study. *J Rheumatol* 2006; **33(3)**:581-587.
5. **Delaney JA**, Opatrny L, Suissa S. Warfarin use and the risk of motor vehicle crash in older drivers. *Br J Clin Pharmacol* 2006; **61(2)**:229-232.
6. **Delaney JA**, Lévesque LE, Etminan M, Suissa S. Furosemide Use and Hospitalization for Benign Prostatic Hyperplasia: Is There a Relationship? *Can J Clin Pharmacol* 2006; **13(1)**:e75-e80.
7. Dial S, **Delaney JA**, Schneider V, Suissa S. Proton Pump Inhibitor use and the risk of treated *Clostridium difficile* associated disease in the community. *CMAJ* 2006; **175(7)**:745-748.
8. Filion KB, **Delaney JA**, Brophy JM, Ernst P, Suissa S. The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. *Pharmacoepidemiol Drug Saf* 2007; **16(1)**:1-4.
9. **Delaney JAC**, Dial S, Barkun A, Suissa S. Antimicrobial drugs and community-acquired *Clostridium difficile*-associated disease, UK. *Emerg Infect Dis* 2007; **13(5)**:761-763.
10. Hébert C, **Delaney JAC**, Hemmelgarn B, Lévesque LE, Suissa S. Benzodiazepines and Older Drivers: A Comparison of Pharmacoepidemiological Study Designs. *Pharmacoepidemiol Drug Saf* 2007; **16(8)**:845-849.
11. Schneider-Lindner V, **Delaney JA**, Dial S, Dascal A, Suissa S. Antibacterial drugs and the risk of infection with methicillin resistant staphylococcus aureus (MRSA) in the community, United Kingdom. *Emerg Infect Dis* 2007; **13(7)**:994-1000.
12. **Delaney JA**, Opatrny L, Brophy JM, Suissa S. Interactions between anti-thrombotic drugs and the risk of gastro-intestinal haemorrhage. *CMAJ* 2007; **177(4)**:347-351.
13. **Delaney JAC**, Daskalopoulou SS, Brophy JM, Steele RJ, Opatrny L, Suissa S. Lifestyle variables and the risk of myocardial infarction in the General Practice Research Database. *BMC Cardiovasc Disord* 2007; **7**:38.
14. **Delaney JA**, Schneider-Lindner V, Brassard P, Suissa S. Prognosis of methicillin resistant staphylococcus aureus (MRSA) infections in the community. *BMC Med* 2008; **6**:2.
15. Lefebvre G/**Delaney JA**, Platt RW. Impact of mis-specification of the treatment model on estimates from a Marginal Structural Model. *Stat Med* 2008; **27(18)**:3629-3642.
16. **Delaney JA**, Opatrny L, Brophy JM, Suissa S. Confounding in database pharmacoepidemiology studies: The example of gastro-intestinal bleeds. *Epidemiology* 2008; **19(2)**:360-361.
17. **Delaney JA**, Moodie EE, Suissa S. Validating the effects of drug treatment on blood pressure in the General Practice Research Database. *Pharmacoepidemiol Drug Saf* 2008; **17(6)**:535-545.
18. Opatrny L, **Delaney JA**, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: A new look. *Br J Clin Pharmacol* 2008; **66(1)**:76-81.

19. Moodie EEM, **Delaney JAC**, Lefebvre G, Platt RW. Missing data in marginal structural models: a comparison of inverse probability weighting and multiple imputation. *Int J Biostat* 2008; 4(1):13.
20. Daskalopoulou SS, **Delaney JA**, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of Statin Therapy Following an Acute Myocardial Infarction: A Population-Based Study. *Eur Heart J* 2008; **29**:2083–2091.
21. Erbel R, **Delaney JAC**, Lehmann N, McClelland RL, Möhlenkamp S, Kronmal RA, Schmermund A, Moebus S, Dragano N, Stang A, Jöckel K-H, Budoff M. Signs of Subclinical Coronary Atherosclerosis in Relation to Risk Factor Distribution in the Multi-Ethnic Study of Atherosclerosis (MESA) and the Heinz Nixdorf Recall (HNR) Study. *Eur Heart J* 2008; **29(22)** :2782-91.
22. **Delaney JA**, Suissa S. Case-crossover designs in Pharmacoepidemiology. *Statistical Methods in Medical Research* 2009;18(1):53-65.
23. **Delaney JAC**, Daskalopoulou SS, Suissa S. Traditional versus marginal structural models to estimate the effectiveness of β -blocker use on mortality after myocardial infarction. *Pharmacoepidemiol Drug Saf* 2009; **18(1)**:1-6.
24. Blagojevic A, **Delaney JA**, Lévesque LE, Dendukuri N, Boivin JF, Brophy JM. Absence of an interaction between statins and clopidogrel after percutaneous coronary intervention: A cohort study. *Pharmacoepidemiol Drug Saf* 2009;18(5):362-9.
25. **Delaney JAC**, Oddson BE, McClelland RL, Psaty BM. Estimating ethnic differences in self-reported new use of antidepressant medications: results from the Multi-Ethnic Study of Atherosclerosis. *Pharmacoepidemiol Drug Saf* 2009;18(7):545-53.
26. **Delaney JA**, McClelland RL, Brown E, Bluemke DA, Vogel-Claussen J, Lai S, Heckbert SR. Multiple imputation for missing with cardiac magnetic resonance imaging data: Results from the Multi-Ethnic Study of Atherosclerosis (MESA). *Can J Cardiol* 2009;25(7):e232-5.
27. Ionescu-Ittu R, **Delaney JAC**, Abrahamowicz M. Assessing the Use of Physician's Prescription Preferences as an Instrumental Variable to Reduce the Impact of Unobserved Confounding in Pharmacoepidemiology. *Pharmacoepidemiol Drug Saf* 2009;18(7):562-71.
28. Folsom AR, **Delaney JAC**, Lutsey PL, Zakai NA, Jenny NS, Polak JF, Cushman M. Associations of Factor VIIIc, D-dimer and Plasmin-Antiplasmin with Incident Cardiovascular Disease and All-Cause Mortality: the Multi-Ethnic Study of Atherosclerosis. *Am J Hematol* 2009;84(6):349-353.
29. **Delaney JA**, Platt RW, Suissa S. The impact of unmeasured baseline effect modification on a marginal structural logistic model: a Monte Carlo study. *Eur J of Epidemiol* 2009;24:343-349.
30. **Delaney JAC**, McClelland RL, Furberg CD, Cooper R, Shea SJ, Burke G, Psaty BM. Time trends in the use of anti-hypertensive medications: results from the Multi-Ethnic Study of Atherosclerosis *Pharmacoepidemiol Drug Saf* 2009;18(9):826-32.
31. Grunfeld C, **Delaney JA**, Wanke C, Currier JS, Scherzer R, Biggs ML, Tien PC, Shlipak MG, Sidney S, Polak JF, O'leary D, Bacchetti P, Kronmal RA; for the study of Fat Redistribution and

- Metabolic Change in HIV Infection (FRAM). Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. *AIDS*. 2009;23(14):1841-9.
32. Boger-Megiddo I, Heckbert SR, Weiss NS, McKnight B, Furberg CD, Wiggins KL, **Delaney JAC**, Siscovick DS, Larson EB, Lemaitre RN, Smith NL, Rice KM, Glazer NL, Psaty BM. MI and stroke risk associated with diuretic-based two-drug antihypertensive therapies: a case-control study. *BMJ* 2010;340:c103.
33. Shrestha S, Irvin MMD, Taylor KD, Wiener HW, Pajewski NM, Haritunians T, **Delaney JAC**, Schambelan M, Polak JF, Arnett DK, Chen YI, Grunfeld C. A Genome-wide Association Study of Carotid Atherosclerosis in HIV-infected Men. *AIDS* 2010; 24(4):583-92.
34. **Delaney JAC**, Oddson BE, Kramer H, Shea S, Psaty BM, McClelland RL. Baseline depressive symptoms are not associated with clinically important levels of incident hypertension during two years of follow-up: the multi-ethnic study of atherosclerosis. *Hypertension* 2010;55(2):408-14
35. **Delaney JA**, Scherzer R, Polak J, Biggs ML, Kronmal R, Chen H, Sidney S, Grunfeld C. Effect of inter-reader variability on outcomes in studies using carotid intima media thickness quantified by carotid ultrasonography. *Eur J Epidemiol* 2010;25(6):385-92.
36. Elmariah S, **Delaney JAC**, O'Brien KD, Budoff MJ, Vogel-Claussen J, Fuster V, Kronmal RA, Halperin JL. Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol* 2010;56(21):1752-9.
37. **Delaney JAC**, Kronmal R, Wanke C, Currier J, Scherzer R, Biggs ML, Shlipak M, Polak J, O'Leary D, Bacchetti P, Grunfeld C. Predictors of increased Carotid Intima-Medial Thickness in HIV infected patients: the Study of Fat Redistribution and Metabolic Change in HIV Infection. *AIDS* 2010;24(14):2201-9.
38. **Delaney JAC**, Biggs ML, Kronmal RA, Psaty BM. Demographic, medical, and behavioral characteristics associated with over the counter non-steroidal anti-inflammatory drug use in a population-based cohort: results from the Multi-Ethnic Study of Atherosclerosis. *Pharmacoepidemiol Drug Saf* 2011;20(1):83-9
39. Wassel CL, Lange LA, Keating BJ, Taylor KC, Johnson AD, Palmer CD, Ho LA, Smith NL, Lange EM, Li Y, Yang Q, **Delaney JA**, Tang W, Tofler G, Redline S, Taylor HA Jr, Wilson JG, Tracy RP, Jacobs DR Jr, Folsom AR, Green D, O'Donnell CJ, Reiner AP. Association of genomic loci from a cardiovascular gene SNP array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the Candidate gene Association Resource (CARE). *Blood* 2011;117(1):268-75.
40. Abrahamowicz MA, Beauchamp ME, Ionescu-Ittu R, **Delaney JA**, Pilote L. New Method for Stabilizing the Variance of Instrumental Variable Physician Preference-Based Estimates of Treatment Effect. *Am J Epidemiol* 2011;174(4):494-502.
41. Etminan M, **Delaney JAC**, Bressler B, Brophy JM. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. *CMAJ* 2011;183(8):899-904.
42. Taylor KC, Lange LA, Zabaneh D, Lange E, Keating BJ, Tang W, Smith NL, **Delaney JA**, Kumari M, Hingorani A, North KE, Kivimaki M, Tracy RP, O'Donnell CJ, Folsom AR, Green D, Humphries

- SE, Reiner AP. A gene-centric association scan for Coagulation Factor VII levels in European and African Americans: the Candidate Gene Association Resource (CARE) Consortium. *Hum Mol Genet* 2011;20(17):3525-34.
43. Djoussé L, Bartz T, Ix JH, Zieman SJ, **Delaney JA**, Mukamal KJ, Gottdiener JS, Siscovick DS, Kizer JR. Adiposity and incident heart failure in older adults: the Cardiovascular Health Study. *Obesity* 2012;20(9):1936-41.
44. Odden MC, Tager IB, van der Laan MJ, **Delaney JAC**, Peralta CA, Katz R, Sarnak MJ, Psaty BM, Shlipak MG. Antihypertensive Medication Use and Change in Kidney Function in Elderly Adults: A Marginal Structural Model Analysis. *The International Journal of Biostatistics* 2011;7(1): 34.
45. Shikuma C, Seto T, Liang CY, Bennett K, De Gruttola V, Gerschenson M, Stein J, Budoff M, Hodis H, **Delaney JA**, Ogata-Arakaki D, Pramyothin P, Chow D. Vitamin D Levels and Markers of Arterial Dysfunction in HIV. *AIDS Res Hum Retroviruses* 2012;28(8):793-7.
46. Ventetuolo CE, Barr RG, Bluemke DA, Jain A, **Delaney JA**, Hundley WG, Lima JA, Kawut SM. Selective Serotonin Reuptake Inhibitor Use Is Associated with Right Ventricular Structure and Function: The MESA-Right Ventricle Study. *PLoS One* 2012;7(2):e30480.
47. Bird ST*, Pepe SR, Etminan M, Liu X, Brophy JM, **Delaney JA**. The association between drospirenone and hyperkalemia: a comparative-safety study. *BMC Clin Pharmacol* 2011;11(1):23.
48. Suissa D, **Delaney JA**, Dial S, Brassard P. Non-Steroidal Anti-Inflammatory Drugs and The Risk of Clostridium Difficile-Associated Disease. *Br J Clin Pharmacol* 2012;74(2):370-5.
49. Kauf TL, Nelson DR, Schelfhout J, **Delaney JA**, Wang PF. Trends in the Prevalence of Thrombocytopenia among Individuals Infected with Hepatitis C Virus in the United States, 1999-2008. *BMC Res Notes* 2012;5(1):142.
50. The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. *Lancet* 2012;379(9822):1214-24. [author 93 of 114]
51. Platt RW, **Delaney JA**, Suissa S. The positivity assumption and marginal structural models: the example of warfarin use and risk of bleeding. *Eur J Epidemiol* 2012;27(2):77-83.
52. Bird ST, Liu W, Brophy JM, Bressler B, **Delaney JA**, Etminan M. Irritable bowel syndrome and drospirenone-containing oral contraceptives; a comparative-safety study. *Curr Drug Saf* 2012;7(1):8-15.
53. Gerhard T, **Delaney JA**, Cooper-Dehoff RM, Shuster J, Brumback BA, Johnson JA, Pepine CJ, Winterstein AG. Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy. *BMC Med Res Methodol* 2012;12(1):119.
54. Elmariah S, **Delaney JA**, Bluemke DA, Budoff MJ, O'Brien KD, Fuster V, Kronmal RA, Halperin JL. Associations of LV Hypertrophy With Prevalent and Incident Valve Calcification: Multi-Ethnic Study of Atherosclerosis. *JACC Cardiovasc Imaging* 2012;5(8):781-8.

55. Bird ST*, Hartzema AG, Brophy JM, Etminan M, **Delaney JA**. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. *CMAJ* 2013;185(2):E115-20.
56. Daskalopoulou SS, Doonan RJ, **Delaney JA**, Pilote L. Different Patterns of Statin Use in Patients with Acute Myocardial Infarction. *Curr Vasc Pharmacol* 2012 Sep 18. [Epub ahead of print]
57. Bird ST*, Hartzema AG, Etminan M, Brophy JM, **Delaney JA**. Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. *Gynecol Endocrinol* 2013;29(4):365-9.
58. Schelfhout JE, Stojanovic DA, Houtchens A, Crane HM, Cachay ER, Brown ER, Napravnik SM, Kitahata MM, Saag MS, Hunt PW, Kauf TL, **Delaney JAC**. Progression of Platelet Counts in Treatment Naïve HIV/HCV Co-Infection. *World Journal of AIDS* 2012 doi:10.4236/wja.2012
59. Etminan M, Bird ST, **Delaney JA**, Bressler B, Brophy JM. Isotretinoin and the risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data. *Arch Dermatol.* 2013;149(2):216-220.
60. Bird ST*, **Delaney JA**, Etminan M, Brophy JM, Hartzema AG. Drospirenone and non-fatal venous thromboembolism: Is there a risk difference by dosage of Ethinyl-Estradiol? *J Thromb Haemost* 2013;11(6):1059-68.
61. Bauer M, **Delaney JA**, Möhlenkamp S, Jöckel KH, Kronmal RA, Lehmann N, Mukamal KJ, Moebus S, Polak JF, Dragano N, Budoff MJ, Erbel R, McClelland RL; Multi-Ethnic Study of Atherosclerosis and the Investigator Group of the Heinz Nixdorf Recall Study. Comparison of Factors Associated with Carotid Intima-Media Thickness in the Multi-Ethnic Study of Atherosclerosis (MESA) and the Heinz Nixdorf Recall Study (HNR). *J Am Soc Echocardiogr* 2013 Jun;26(6):667-73.
62. Bird ST, Brophy JM, Hartzema AG, **Delaney JA**, Etminan M. Male breast cancer and 5-alpha reductase inhibitors, finasteride and dutasteride. *J Urol* 2013 [in press]
63. Bird ST*, Etminan M, Brophy JM, Hartzema AG, **Delaney JA**. Risk of acute kidney injury associated with the use of fluoroquinolones. *CMAJ* 2013;185(10):E475-82.
64. Cooper-DeHoff RM, Bird ST, Nichols GA, **Delaney JA**, Winterstein AG. Antihypertensive Drug Class Interactions and risk for Incident Diabetes; a Nested Case Control Study. *Journal of the American Heart Association* 2013;2:e000125,
65. Budoff MJ, Möhlenkamp S, McClelland R, **Delaney JA**, Bauer M, Jöckel HK, Kälsch H, Kronmal R, Nasir K, Lehmann N, Moebus S, Mukamal K, Erbel R; Multi-Ethnic Study of Atherosclerosis and the Investigator Group of the Heinz Nixdorf RECALL Study. A comparison of outcomes with coronary artery calcium scanning in unselected populations: The Multi-Ethnic Study of Atherosclerosis (MESA) and Heinz Nixdorf RECALL study (HNR). *J Cardiovasc Comput Tomogr* 2013;7(3):182-91.
66. **Delaney JA**, Lehmann N, Jöckel KH, Elmariah S, Psaty BM, Mahabadi AA, Budoff M, Kronmal RA, Nasir K, O'Brien KD, Möhlenkamp S, Moebus S, Dragano N, Winterstein AG, Erbel R, Kälsch H. Associations between aspirin and other non-steroidal anti-inflammatory drugs and aortic valve or

coronary artery calcification: The Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. *Atherosclerosis* 2013;229(2):310-6.

67. Muñoz MA*, Liu W, **Delaney JA**, Brown E, Mugavero MJ, Mathews WC, Napravnik S, Willig JH, Eron JJ, Hunt PW, Kahn JO, Saag MS, Kitahata MM, Crane HM. Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. *J Acquir Immune Defic Syndr* 2013;64(3):254-60.

68. **Delaney JA**, Jensky NE, Criqui MH, Whitt-Glover MC, Lima JA, Allison MA. The association between physical activity and both incident coronary artery calcification and ankle brachial index progression: The Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 2013;230(2):278-83.

69. Wheeler AL, Scherzer R, Lee D, **Delaney JA**, Bacchetti P, Shlipak MG, Sidney S, Grunfeld C, Tien PC. HIV/HCV coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection. *AIDS* 2014;28(1):49-58.

70. Elmariah S, Budoff MJ, **Delaney JA**, Hamirani Y, Eng J, Fuster V, Kronmal RA, Halperin JL, O'Brien KD. Risk factors associated with the incidence and progression of mitral annulus calcification: The multi-ethnic study of atherosclerosis. *Am Heart J* 2013;166(5):904-12.

71. Bird ST*, **Delaney JA**, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. *BMJ* 2013;347:f6320.

72. Ton TG, Biggs ML, Comer D, Curtis L, Hu SC, Thacker EL, Searles Nielsen S, **Delaney JA**, Landsittel D, Longstreth WT Jr, Checkoway H, Jain S. Enhancing case ascertainment of Parkinson's disease using Medicare claims data in a population-based cohort: the Cardiovascular Health Study. *Pharmacoepidemiol Drug Saf* 2014;23(2):119-27.

73. Knox CA, **Delaney JA**, Winterstein AG. Anti-diabetic drug utilization of pregnant diabetic women in us managed care. *BMC Pregnancy Childbirth* 2014;14(1):28.

/* divider */

74. Camelo Castillo W, **Delaney JA**, Stürmer T. The challenges of comparing results between placebo controlled randomized trials and non-experimental new user, active comparator cohort studies: the example of olmesartan. *Pharmacoepidemiol Drug Saf* 2014 Apr;23(4):357-60.

75. Lefebvre G, **Delaney JA**, McClelland RL. Extending the Bayesian Adjustment for Confounding algorithm to binary treatment covariates to estimate the effect of smoking on carotid intima-media thickness: the Multi-Ethnic Study of Atherosclerosis. *Stat Med* 2014;33(16):2797-813.

76. Crane HM, Heckbert SR, Drozd DR, Budoff MJ, **Delaney JA**, Rodriguez C, Paramsothy P, Lober WB, Burkholder G, Willig JH, Mugavero MJ, Mathews WC, Crane PK, Moore RD, Napravnik S, Eron JJ, Hunt P, Geng E, Hsue P, Barnes GS, McReynolds J, Peter I, Grunfeld C, Saag MS, Kitahata MM; for the Centers for AIDS Research Network of Integrated Clinical Systems Cohort Investigators. Lessons Learned From the Design and Implementation of Myocardial Infarction Adjudication Tailored for HIV Clinical Cohorts. *Am J Epidemiol* 2014;179(8):996-1005.

77. Yeboah J, **Delaney JA**, Nance R, McClelland RL, Polak JF, Sibley CT, Bertoni A, Burke GL, Carr JJ, Herrington DM. Mediation of Cardiovascular Risk Factor Effects Through Subclinical Vascular Disease: The Multi-Ethnic Study of Atherosclerosis. *Arterioscler Thromb Vasc Biol* 2014 34(8):1778-83.
78. Weng LC, Tang W, Rich SS, Smith NL, Redline S, O'Donnell CJ, Basu S, Reiner AP, **Delaney JA**, Tracy RP, Palmer CD, Young T, Yang Q, Folsom AR, Cushman M. A genetic association study of D-dimer levels with 50K SNPs from a candidate gene chip in four ethnic groups. *Thromb Res* 2014 Aug;134(2):462-7.
79. Winterstein AG, Kubilis P, Bird S, Cooper-DeHoff RM, Nichols GA, **Delaney JA**. Misclassification in assessment of diabetogenic risk using electronic health records. *Pharmacoepidemiol Drug Saf* 2014 Aug;23(8):875-81.
80. Yeboah J, Erbel R, **Delaney JC**, Nance R, Guo M, Bertoni AG, Budoff M, Moebus S, Jöckel KH, Burke GL, Wong ND, Lehmann N, Herrington DM, Möhlenkamp S, Greenland P. Development of a new diabetes risk prediction tool for incident coronary heart disease events: The Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. *Atherosclerosis* 2014;236(2):411-417.
81. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmieri J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RG, de Borst GJ, de Jong PA, Algra A, Spiering W, der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D; DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJ, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SR, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WM, Redline S, Patel SR, Whittaker JC, Hamsten A, **Delaney JA**, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogeveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimäki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevodova M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet* 2014 pii: S0140-6736(14)61183-1.
82. Gepner AD, Young R, **Delaney JC**, Tattersall MC, Blaha MJ, Post WS, Gottesman RF, Kronmal R, Budoff MJ, Burke GL, Folsom AR, Liu K, Kaufman J, Stein JH. A Comparison of Coronary Artery Calcium Presence, Carotid Plaque Presence, and Carotid Intima-Media Thickness for Cardiovascular Disease Prediction in the Multi-Ethnic Study of Atherosclerosis (MESA). *Circulation: Cardiovascular Imaging*. (In press)
83. Ma W, Wu JH, Wang Q, Lemaitre RN, Mukamal KJ, Djoussé L, King IB, Song X, Biggs ML, **Delaney JA**, Kizer JR, Siscovick DS, Mozaffarian D. Prospective association of fatty acids in the de

novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study. *Am J Clin Nutr.* 2015 Jan;101(1):153-63.

84. Jain S, Himali J, Beiser A, Ton TG, Kelly-Hayes M, Biggs ML, **Delaney JA**, Rosano C, Seshadri S, Frank SA. Validation of secondary data sources to identify Parkinson disease against clinical diagnostic criteria. *Am J Epidemiol.* 2015 Feb 1;181(3):185-90.

85. Ix JH, Biggs ML, Mukamal K, Djousse L, Siscovick D, Tracy R, Katz R, **Delaney JA**, Chaves P, Rifkin DE, Hughes-Austin JM, Garimella PS, Sarnak MJ, Shlipak MG, Kizer JR. Urine Collagen Fragments and CKD Progression-The Cardiovascular Health Study. *J Am Soc Nephrol.* 2015 Feb 5. pii: ASN.2014070696.

86. Yeboah J, Sillau S, **Delaney JC**, Blaha MJ, Michos ED, Young R, Qureshi WT, McClelland R, Burke GL, Psaty BM, Herrington DM. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA). *Am Heart J* 2015;169(3):387-395.e3.

87. Tang W, Cushman M, Green D, Rich SS, Lange LA, Yang Q, Tracy RP, Tofler GH, Basu S, Wilson JG, Keating BJ, Weng LC, Taylor HA, Jacobs DR Jr, **Delaney JA**, Palmer CD, Young T, Pankow JS, O'Donnell CJ, Smith NL, Reiner AP, Folsom AR. Gene-centric approach identifies new and known loci for FVIII activity and VWF antigen levels in European Americans and African Americans. *Am J Hematol.* 2015 Jun;90(6):534-40.

88. Wang Q, Imamura F, Ma W, Wang M, Lemaitre RN, King IB, Song X, Biggs ML, **Delaney JA**, Mukamal KJ, Djousse L, Siscovick DS, Mozaffarian D. Circulating and dietary trans fatty acids and incident type 2 diabetes in older adults: the Cardiovascular Health Study. *Diabetes Care.* 2015 Jun;38(6):1099-107.

89. Tattersall MC, Guo M, Korcarz CE, Gepner AD, Kaufman JD, Liu KJ, Barr RG, Donohue KM, McClelland RL, Delaney JA, Stein JH. Asthma predicts cardiovascular disease events: the multi-ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2015 Jun;35(6):1520-5.

90. Duran L, Rodriguez C, Drozd D, Nance RM, **Delaney JA**, Burkholder G, Mugavero MJ, Willig JH, Warriner AH, Crane PK, Atkinson BE, Harrington RD, Dhanireddy S, Saag MS, Kitahata MM, Crane HM. Fructosamine and Hemoglobin A1c Correlations in HIV-Infected Adults in Routine Clinical Care: Impact of Anemia and Albumin Levels. *AIDS Res Treat.* 2015;2015:478750.

91. Yeboah J, Polonsky TS, Young R, McClelland RL, **Delaney JC**, Dawood F, Blaha MJ, Miedema MD, Sibley CT, Carr JJ, Burke GL, Goff DC, Psaty BM, Greenland P, Herrington DM. Utility of Non-Traditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 ACC/AHA Cholesterol Guidelines. *Circulation* 2015;132(10):916-22.

92. Spieker AJ, **Delaney JA**, McClelland RL. Evaluating the treatment effects model for estimation of cross-sectional associations between risk factors and cardiovascular biomarkers influenced by medication use. *Pharmacoepidemiol Drug Saf* 2015 Sep 30.

93. Reina SA, Llabre MM, Allison MA, Wilkins JT, Mendez AJ, Arnan MK, Schneiderman N, Sacco RL, Carnethon M, **Delaney JA**. HDL cholesterol and stroke risk: The Multi-Ethnic Study of Atherosclerosis. *Atherosclerosis* 2015;243(1):314-9.

/* divider 2015/2016 */

In preparation:

94. **Joseph AC Delaney**, Xiaoyan Y in, João Daniel Fontes, Erin Wallace, Na Wang, Bradley Hammill, Emelia Benjamin, Lesley Curtis, Susan R. Heckbert. Health care costs for Medicare beneficiaries with atrial fibrillation in the Cardiovascular Health Study and the Framingham Heart Study.

* Student first author, in cases where I am on the student's committee (and was highly involved) or acted as the student's major advisor. For Monica Muñoz, I was the primary mentor and she was my MS student when the paper was written but another student (whom I also was working with was 2nd author) and the clinical expert (Heidi Crane) was senior.

b) Other refereed scholarly publications

1. **Delaney JAC**, Seeger J. Sensitivity analysis. In: Velentgas P, Dreyer NA, Nourjah P, et al., eds. *Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide*. AHRQ Publication No. 12(13)-EHC099. Rockville, MD: Agency for Healthcare Research and Quality; January 2013: Chapter 11, pp. 145-60.

c) Books and book chapters

Not applicable

d) Other non-refereed published scholarly publications

Notes

1. **Delaney JA**. Tracking system for studies should be in place. *BMJ* 2004; **329(7458)**:173.
2. **Delaney JA** and Quail J. Universal care. *CMAJ* 2004; **170(10)**:1520.
3. **Delaney JA**. The best type of trial. *CMAJ* 2004; **170(12)**:1772.
4. Brennan AS and **Delaney JA**. Medical privacy is important. *CMAJ* 2004; **170(10)**:1518.
5. **Delaney JA**, Palko M and Brennan AS. Canadian adverse events study. *CMAJ* 2004; **171(8)**:833-834.
6. Quail J, **Delaney JA** and Oddson B. How children see themselves. *CMAJ* 2004; **171(9)**:1024-1025.

7. **Delaney JA**. Neural tube defects. *CMAJ* 2005; **172(2)**:157-158.
8. **Delaney JA** and Brennan AS. Clinical trial budgets. *CMAJ* 2005; **172(5)**:616-617.
9. Filion KB and **Delaney JA**. Cognitive therapy and preventing suicide attempts. *JAMA* 2005; **294(22)**:2847-2848.
10. Dial S, **Delaney JA**, Barkun A and Suissa S. Gastric acid-suppressive agents and risk of Clostridium difficile-associated disease - Reply. *JAMA* 2006; **295(22)**:2600-2601.
11. **Delaney JA**, Opatrny L and Suissa S. Authors' response: Warfarin, medicinal drugs and road traffic accidents. *Br J Clin Pharmacol* 2006; **62(5)**:628.
12. Dial S, **Delaney JA**. Possible patient overlap in studies. *CMAJ* 2007; **176(6)**:809.
13. **Delaney JA**, Opatrny L, Brophy JM, Suissa S. Combined antithrombotic therapy. *CMAJ* 2008; **178(3)**:327-328.
14. Crane HM, Heckbert SR, Drozd DR, Budoff MJ, **Delaney JA**, Rodriguez C, Paramsothy P, Lober WB, Burkholder G, Willig JH, Mugavero MJ, Mathews WC, Crane PK, Moore RD, Napravnik S, Eron JJ, Hunt P, Geng E, Hsue P, Barnes GS, McReynolds J, Peter I, Grunfeld C, Saag MS, Kitahata MM. The authors reply. *Am J Epidemiol* 2014; **180(4)**:450.

8. Patents and Other Intellectual Property

None

9. Funding History

1. Sponsor: Canadian Institutes of Health Research, PI: (JM Brophy), 6/1/2006 – 6/1/2008, "The effect of Diabetes Mellitus on the development, treatment, and outcomes of congestive heart failure" \$99,926. Role: Co-Investigator
2. Sponsor: Canadian Institutes of Health Research, PI: (P Ernst), 1/1/2008 – 1/1/2009, "The Adverse effects of inhaled corticosteroids in patients with respiratory disease." \$77,132. Role: Co-Investigator
3. AHRQ (R21 HS019516-01) *sub-contract*. PI: (H Crane), 10/1/2010 – 9/30/2012, "Comparative effectiveness of lipid-lowering and antihypertensive medications among patients infected with HIV". \$46,881. Role: Sub-contract PI
4. New Pharmacy Faculty Research Awards Program, PI: (JA Delaney), 2010-2011. "Secondary analysis of prospective cohort data from the Multi-Ethnic Study of Atherosclerosis". \$8,820. Role: Principal Investigator.
5. CIHR (Operating Grant), PI: (M Abrahamowicz), "New Statistical Methods for Population-based Studies of Comparative Effectiveness and Safety of Medications: Development, Validation and Applications". March 2011. Role: International Collaborator

6. NIH (R21HL120394-01), PI: (JA Delaney/R Kaplan), “CVD and inflammation across the lifespan in HIV infected adults and children” July 2013. Role: Principal Investigator

7. NIH (R56HL126538), PI: (H Crane/K Crothers/S Heckbert), “Cardiovascular, Pulmonary & Hematological Disease in HIV: Prevention & Treatment”. September 2014. Role: Co-Investigator

8. NIH (U01DA037702), PI: (R Kronmal/H Crane), “Seek, Test, Treat, and Retain Data Harmonization Coordinating Center”. March 2014. Role: Co-Investigator

9 NIH (R01HL126538), PI: (H Crane/S Heckbert/J Delaney), “CARDIOVASCULAR, PULMONARY & HEMATOLOGICAL DISEASE IN HIV: PREVENTION & TREATMENT”. September 2015. Role: Multiple PI

10. NIH (N01HC95159), PI: (R Kronmal/R McClelland), “MESA”. August 2015. Role: Co-investigator

Failed Funding

1. NIH (R01), PI: (R McClelland). “Statistical Methods for Cardiovascular Disease”. November 2009. Role: Co-investigator

2. NIH (R01), PI: (J Shuster). “Cardiovascular Meta-Analyses Revisited”. June 2010. Role: Co-investigator

3. UF/Moffat (Seed Money Grant), PI: (FT Odedina). “Case-Control Study of Prostate Cancer in West African men: A Feasibility Study”. July 2010. Role: Co-Investigator

4. UF Opportunity Grant, PI: (R Cooper-DeHoff). “Utilization of Chronic Medications with Adverse Metabolic Effects as a Predictor of Incident Diabetes”. November 2010. Role: Co-Investigator

5. NIH (P20), PI: (FT Odedina). “Feasibility Studies for Collaborative Interaction for Minority Institution”. March 2011. Role: Co-Investigator

6. NIH (R21), PI: (J Delaney). “The association between prescription medication use and motor vehicle crashes”. June 2011. Role: Principal Investigator

7. NIH (R01), PI: (J Shuster). “Meta-analysis of low event trials: Appropriate and inappropriate methods”. June 2011. Role: Co-investigator

8. NIH (T32), PI: A Hartzema). “Training for safe med use in the unborn, the newly born and young children”. June 2011. Role: Co-Investigator

9. NIH (R01), PI: (R McClelland). “Distal Vein Thrombosis: Anticoagulation vs. Surveillance (DiVeTAS): Data Coordinating Center”. June 2011. Role: Co-investigator

10. NIH (R01), PI: (J Shuster). “Meta-analysis of low event trials: Appropriate and inappropriate methods”. March 2012 (resubmission). Role: Co-investigator

11. NIH (R01), PI: (H Crane). “Metabolic Effects of 2nd Generation Antipsychotic medication in people with HIV”. March 2012. Role: Co-investigator
12. NIH (R03), PI: (FT Odedina). “Prostate Cancer Characteristics of African-Born Compared to Native-Born Blacks”. March 2012. Role: Co-investigator
13. NIH (R03) PI: Allen. Trajectories in Successful Aging and Their Impact on Medicare Costs: The Cardiovascular Health Study. February 2013. Role: Sub-contract PI
14. NIH (R21) PI Dublin. Prescription opioids and cardiovascular outcomes. Role: Co-Investigator
15. NIH (R21) PI: Crane. Comparative effectiveness of SSRIs and SGAs among patients aging with HIV. October 2012. Role: co-PI
16. NIH (R21) PI: Delaney. Methodological issues in assessing Associations between medication use an left ventricular mass, volume, and systolic function in a multi-ethnic cohort. October 2012. Role: PI
17. NIH (U01) PI: Kerr/Bennett. Mechanisms of HIV-Related Lung Disease Data Coordinating Center (DCC). March 2013. Role: Co-Investigator.
18. NIH (R01) PI: Young/Delaney. Bone/artery calcification and cytokines: Multi-Ethnic Study of Atherosclerosis. February 2014. Role: Co-PI
19. NIH (R21): Delaney/Averill. Ethnic differences in potassium/sodium associations with cardiovascular events. October 2014. Role: co-PI
20. NIH (R21): Psaty (sub-contract PI). Opioids & Benzodiazepines and Risk of Heart Attack. Role: Co-investigator

Submitted Funding

1. NIH (R21): Associations between medication use and left ventricular mass plus systolic function in a multi-ethnic cohort. October 2015.

10. Public Health Practice Activities

None

11. Conferences and Symposia

Invited

1. A comparison of pharmacoepidemiologic study designs. Biostatistics Seminar, Department of Epidemiology and Biostatistics, McGill University, October 2005.
2. Defining Clostridium Difficile infections in the General Practice Research Database. Divisional Seminar, Division of Clinical Epidemiology, Royal Victoria Hospital, Montreal, March 2006.

3. Marginal structural Models. Divisional seminar, Division of Clinical Epidemiology, Montreal General Hospital, Montreal, March 2006.
4. Methicillin resistant staphylococcus aureus infections in the community: What can we learn from databases? Departmental Seminar, Department of Epidemiology, Biostatistics and Occupational Health, December 2006.
5. Drug-Drug interactions and gastro-intestinal bleeds in the General Practice Research Database. Divisional Seminar, Division of Clinical Epidemiology, McGill University Health Center, Montreal, March 2007.
6. Assessing the risks associated with warfarin therapy and related methodological considerations. Student Seminar Series, Department of Biostatistics, University of Washington, Seattle, January 2008.
7. Assessing the risks associated with warfarin therapy and related methodological considerations. Works in Progress Seminar Series. Collaborative Health Studies Coordinating Center, University of Washington, Seattle, February 2008.
8. Inverse probability weighting as a causal inference technique: challenges and opportunities. Department of Clinical Epidemiology, Vancouver General Hospital, Vancouver, March 2008.
9. Comparison of Measures of Carotid Intimal-Medial Thickness Between HIV Infected and Normal Subjects: Methodological Concerns. Collaborative Health Studies Coordinating Center, University of Washington, Seattle, October 2008.
10. Sub-clinical disease measures on HIV Infected and uninfected participants. Student Seminar Series, Department of Biostatistics, University of Washington, Seattle, October 2008
11. Bayesian model averaging versus backward p-value selection for predictive variable selection in FRAM: A work in progress. Collaborative Health Studies Coordinating Center, University of Washington, Seattle, June 2009.
12. Blood Pressure in Administrative Databases. Department of Pharmaco-Epidemiology. Brigham and Women's Hospital, Boston, MA, November 2009.
13. Examples of using inverse probability weighting in pharmacoepidemiology. Department of Epidemiology. University of Washington. November 2009.
14. Inverse Probability Weighting & Pharmacoepidemiology. College of Pharmacy. University of Florida. December 2009.
15. Oral contraceptives and the risk of gallbladder disease: a comparative safety study. Clinical and Translational Science Institute Research Day. University of Florida. June 2011.
16. Comparative Safety of Oral Contraceptives. Group Health Research Institute. Seattle, WA. November 2011.
17. Hypertension and Depression: Bias, drug adverse event, or actual association. University of Toronto. February 2012.

18. Marginal Structural Models. Part of the New Design and Analytical Methods in Outcomes and Comparative Effectiveness Research Seminar. University of Alabama at Birmingham. February 2012.
19. NSAID use and calcification in the coronary arteries or aortic valves in MESA and HNR: the challenges of inference in pharmacoepidemiology. Cardiovascular Health Research Unit. University of Washington. November 2012.
20. Causal mediation analysis: the example of traditional risk factors and sub-clinical measures of atherosclerosis. Child and Family Research Institute. University of British Columbia. February 2012
21. Cost-Effectiveness studies using CMS-augmented data in the Cardiovascular Health Study: some methodological issues and early results. CHSCC Seminar. University of Washington. March 2013.
22. Extending Heckman's Treatment Model to Non-Additive Treatment Effects. Spieker AJ, Delaney JA, McClelland RM. Joint Statistics Meeting 2015.
23. R Fredericksen, D Drozd, **JAC Delaney**, R Nance, WC Matthews], K Mayer, G Burkholder, J Willig, S Napravnik, J Eron, K Christopoulos, E Geng, M Mugavero, J McReynolds, G Barnes, W Lober, ME McCaul, H Hutton, G Chander, R Moore, MM Kitahata, PK Crane, M Saag, HM Crane for CNICS. Lessons from implementing and collecting PROs for HIV care and research: results from 10,000 patients. PHO Inaugural Conference, Philadelphia, May, 2015.

Published Abstracts

1. Filion KB, **Delaney JAC**, Brophy JM, Ernst P and Suissa S. The impact of over-the-counter simvastatin on the number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. *J Am Coll Cardiol* 2006; (**Suppl A**) **47**:316A-317A.
2. Levesque LE, **Delaney JA**, Etminan M and Suissa S. Pharmacologic Interventions for the Prevention of Alzheimer's Disease: An Example of Reverse Protopathic Bias. *Pharmacoepidemiol Drug Saf* 2006; **15**: S31.
3. **Delaney JA**, Dial S, Barkun AN and Suissa S. Quinolone Use and the Risk of Community-Acquired *Clostridium Difficile* in the United Kingdom. *Pharmacoepidemiol Drug Saf* 2006; **15**: S29.
4. Schneider V, Dial S, **Delaney JA**, Dascal A and Suissa S. Antibacterial Drugs and the Risk of Infection with Methicillin Resistant *Staphylococcus Aureus* (MRSA) in the Community. *Pharmacoepidemiol Drug Saf* 2006; **15**: S27-28.
5. Assouline S, **Delaney JA**, Gambacorti C and Suissa S. Higher prevalence of prior prostate cancer in patients diagnosed with chronic myelogenous leukemia. *Blood* 2006; **108** (**11**):283B.
6. Schneider-Lindner V, **Delaney JA** and Suissa S. Matching to Prevent Bias in Cohort Studies with Time-Varying Exposures. *Am J Epidemiol* 2007; **165** (**11**):S35.
7. **Delaney JA**, Brophy JM, Steele RJ, Opatrny L and Suissa S. Multiple Imputation for Body Mass Index in the General Practice Research Database. *Am J Epidemiol* 2007; **165** (**11**):S108.

8. Wilchesky M, Platt RW, **Delaney JA**, McDonald S, Dial S and Suissa S. The causal effect of prescription drugs on community-acquired Clostridium Difficile associated disease: A marginal structural models analysis. *Am J Epidemiol* 2007; **165 (11)**:S65.
9. Opatrny L, **Delaney JA** and Suissa S. Gastrointestinal bleed risk with the use of Selective Serotonin Receptor Antagonists: A New Look. *Pharmacoepidemiol Drug Saf* 2007; **16**: S8-S9.
10. **Delaney JA**, Lefebvre G and Platt RW. Variable Selection for Marginal Structural Models. *Pharmacoepidemiol Drug Saf* 2007; **16**: S32-S33.
11. Daskalopoulou SS, **Delaney JAC**, Filion KB, Brophy JM, Mayo NE and Suissa S. The Effect of Changes in Statin Prescribing on Secondary Prevention after the First Acute Myocardial Infarction. *Pharmacoepidemiol Drug Saf* 2007; **16**: S43.
12. **Delaney JA**, Opatrny L, Brophy JM and Suissa S. Anti-thrombotic Drug-Drug Interactions and the Risk of Gastro-Intestinal Bleeding. *Pharmacoepidemiol Drug Saf* 2007; **16**: S52.
13. Blagojevic A, Dendukuri N, **Delaney JAC**, Boivin JF and Brophy JM. An interaction between statins and clopidogrel – A cohort study with time-dependent analysis. *Pharmacoepidemiol Drug Saf* 2007; **16**: S120-S121.
14. **Delaney JAC**, Platt RW, Suissa S. Large and variable inverse probability weights in a marginal structural model analysis of warfarin use and the risk of bleeding. *Am J Epidemiol* 2008; **167(Suppl)**:S48.
15. **Delaney JAC**, McClelland RL, Furberg CD, Cooper R, Shea SJ, Psaty BM. Time trends in the use of anti-hypertensive medications: results from the Multi-Ethnic Study of Atherosclerosis. *Am J Epidemiol* 2008; **167(Suppl)**:S119.
16. Ionescu-Ittu R, **Delaney JAC**, Abrahamowicz M. Bias-Variance Trade-off in Pharmacoepidemiological Studies using Instrumental Variables. *Am J Epidemiol* 2008; **167(Suppl)**:S138.
17. Ionescu-Ittu R, Abrahamowicz M, **Delaney JAC**. Assessment of brookhart's instrumental variable approach in pharmacoepidemiology: The impact of using a weak instrument. *Pharmacoepidemiol Drug Saf* 2008; **17**: S202.
18. Elmariah S, O'Brien KD, Budoff MJ, Vogel-Claussen J, **Delaney JAC**, Fuster V, Kronmal RA, Halperin JL. The Relationship of Bisphosphonate Use to the Prevalence of Aortic Valve Calcification in Women: The Multiethnic Study of Atherosclerosis. *J Am Coll Cardiol* 2009; **53(10)**: A461.
19. **Delaney JAC**, Oddson BE, McClelland RL, Psaty BM. Correcting for Non-Random Loss to Follow-up When Estimating Ethnic Differences in the Utilization of Antidepressant Medications: The Multi-Ethnic Study of Atherosclerosis. *Am J Epidemiol* 2009; **169 (Suppl)**:S13.
20. Ionescu-Ittu R, Abrahamowicz M, **Delaney JAC**. Assessing the Linearity Assumption for the Instrumental Variable Analysis with Binary Outcomes. *Am J Epidemiol* 2009; **169 (Suppl)**:S115.

21. Elmariah S, Valentin Fuster, Kronmal RA, Budoff MJ, Vogel-Claussen J, O'Brien KD, **Delaney JA**, Halperin JL. Bisphosphonate Use and the Prevalence of Cardiovascular Calcification in Women: The Multi-Ethnic Study of Atherosclerosis. *Circulation* 2009; 120(18): S538.
22. Elmariah S, O'Brien KD, Budoff MJ, Vogel-Claussen J, **Delaney JAC**, Fuster V, Kronmal RA, Halperin JL. The Relationship of Bisphosphonate Use to the Prevalence of Aortic Valve Calcification in Women: The Multiethnic Study of Atherosclerosis. *JACC* 2009; 53(10): A461.
23. Crane HM, **Delaney JAC**, Brown E, Willig JW, Mugavero M, Hunt PW, Rodriguez B, Matthews WC, Saag M, Kitahata MM. Lipid Levels among Antiretroviral (ARV) Naïve HIV-Infected Individuals in Routine Care. *Pharmacoepidemiol Drug Saf* 2010; **19**: S196.
24. **Delaney JAC**, Oddson BE, Kramer H, Shea S, Psaty BM, McClelland RL. Can Tricyclic Antidepressant Use Explain the Observed Associations between Baseline Depressive Symptoms and Incident Hypertension? *Pharmacoepidemiol Drug Saf* 2010; **19**: S128.
25. Abrahamowicz M, Beauchamp ME, Ionescu-Ittu R, **Delaney JAC**. New Method for Stabilizing the Variance of Instrumental Variable Physician Preference-Based Estimates of Treatment Effect. *Pharmacoepidemiol Drug Saf* 2010; **19**: S214.
26. **Delaney JAC**, Bitton A, Suissa S. Diuretic Use and the Risk of Gastrointestinal Bleeding in the United Kingdom General Population. *Pharmacoepidemiol Drug Saf* 2010; **19**: S216.
27. **Delaney JAC**, Platt RW, Suissa S. Using Inverse Probability Weighting To Estimate Warfarin Adverse Effects: Concerns with Large and Variable Inverse Probability Weights. *Pharmacoepidemiol Drug Saf* 2010; **19**: S227.
28. **Delaney JAC**, Scherzer R, Biggs ML, Shlipak MG, Polak JF, Currier JS, O'Leary D, Tien P, Wanke C, Kronmal RA, Bacchetti P, Grunfeld C. Associations between Anti-Retroviral Drug Use and HIV-Specific Risk Factors with Carotid Intima-Media Thickness: The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). *Pharmacoepidemiol Drug Saf* 2010; **19**: S234.
29. Elmariah S, **Delaney JA**, O'Brien KD, Budoff MJ, Vogel-Claussen J, Fuster V, Kronmal RA, Halperin JL. Bisphosphonate use and the prevalence of cardiovascular calcification in women: The Multi-Ethnic Study of Atherosclerosis. *J Invest Med* 2010; 58(7): 589.
30. Elmariah S, O'Brien KD, Budoff MJ, Bluemke D, **Delaney JA**, Fuster V, Kronmal RA, Halperin JL. Relationship between left ventricular mass and aortic valve calcification: The Multi-Ethnic Study of Atherosclerosis. *J Invest Med* 2010; 58(7): 587.
31. Odden MC, Tager IB, Van der Laan MJ, **Delaney JA**, Peralta CA, Katz R, Sarnak MJ, Psaty BM, Shlipak MG. Antihypertensive medication use and change in kidney function in the elderly: A marginal structural models analysis. *Am J Epidemiol* 2010; **171 (Suppl)**:S150
32. Knox CA, **Delaney JA**, Winterstein AG. Association of Caesarian section delivery among pregnant women with diabetes. *Am J Epidemiol* 2010; **173 (Suppl)**:S152.
33. Tang WH, Cushman M, Basu S, Green D, Reiner AP, **Delaney JA**, Lange LA, Smith NL, Tracy RP, Wilson JG, Tofler G, Yang QO, Keating BJ, Taylor H, Jacobs D, Donnell CJO, Folsom AR.

- Gene-Centric Approach Identifies New and Known Loci for Factor VIII Activity and Von Willebrand Factor Antigen In the Candidate Gene Association Resource (CARE) Consortium. *Blood* 2010; **116** (21):353.
34. Eworuke E, **Delaney JAC**. Maternal Predictors of Preterm Birth: an Analysis of US Birth Data. *Am J Epidemiol* 2010; **173** (Suppl):S133.
35. **Delaney JA**, Brophy JM, Etminan M. The Comparative Safety of Drospirenone for Gallbladder Disease among Women Taking Oral Contraceptives *Pharmacoepidemiol Drug Saf* 2011; 20: S258.
36. Jalbert JJ, Chen CY, Schneeweiss S, Hammill BG, Dreyer NA, **Delaney JA**, Gerhard T, Setoguchi S. Database Linkage and Methodological Issues in Comparative Effectiveness Research (CER) of Medical Devices vs. Medications: Lessons from an Ongoing Project. *Pharmacoepidemiol Drug Saf* 2011; 20: S18.
37. Bird S, Liu X, Pepe S, Brophy J, Etminan M, **Delaney J**. The Association between Drospirenone and Hyperkalemia among Women Taking Oral Contraceptives. *Pharmacoepidemiol Drug Saf* 2011; 20: S72.
38. Liu W, Munoz MA, **Delaney JA**, Brown E, Mugavero MJ, Matthews C, Napravnik S, Willig JH, Saag MS, Kitahata MM, Crane HM. Comparative Effectiveness of Fish Oil, Atorvastatin and Fibrates for Lowering Triglyceride Levels among HIV-Infected Patients. *Pharmacoepidemiol Drug Saf* 2011; 20: S187.
39. Pepe S, Liu X, Bird S, **Delaney J**, Brophy J, Etminan M. Utilization of Drug Therapy with Spironolactone in Patients Taking Drospirenone Versus Levonorgestrel. *Pharmacoepidemiol Drug Saf* 2011; 20: S77.
40. Cooper-DeHoff RM, Bird ST, Nichols GA, **Delaney JC**, Winterstein AG. Association of antihypertensive drug classes, alone or in combination with incident diabetes: a nested case-control study. *Circulation*. 2012;126:A11073. Presented at the American Heart Association 2012 Scientific Sessions, Los Angeles, CA.
41. Cooper-DeHoff RM, Garvan C, **Delaney JA**, Winterstein AG, Bavry A, Howard BV, Chen C, Manson J, Phillips LS, Liu S, Song Y, Shorr RI, Limacher M, and Women's Health Initiative Investigators. Chronic utilization of medications with metabolic effects and risk for incident diabetes in postmenopausal women. *Circulation*. 2012;126:A10050. Presented at the American Heart Association 2012 Scientific Sessions, Los Angeles, CA.
42. Winterstein AG, **Delaney JA**, Kubilis P, Crystal S, Gerhard T. Inclusion of variables associated with exposure but not outcome can compromise propensity score-based adjustments – examination of a real-life example in pediatric psychopharmacology. 29th International Conference of Pharmacoepidemiology, Aug 23-28, Montreal, Canada. *Pharmacoepi Drug Saf* 2013;22:(Suppl.1):232.
43. Liu W, Antonelli PJ, Dahm P, Gerhard T, **Delaney JAC**, Segal R, Crystal S, Winterstein AG. Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. *Pharmacoepi Drug Saf* 2014;23(S1):492-493.

44. Winterstein AG, Cooper-DeHoff R, Kubilis P, Nichols G, **Delaney JAC**. Diabetogenic effects of atypical antipsychotics – exploration of measurement bias. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. *Pharmacoepi Drug Saf* 2014;23(S1):142-143.

45. Liu W, Dahm P, Gerhard T, Antonelli P, **Delaney JC**, Winterstein AG. Utilization of phosphodiesterase type 5 (PDE5) inhibitors for erectile dysfunction among commercially insured adults in the United States. 30th Conference of Pharmacoepidemiology & Therapeutic Risk Management, October 24-27, 2014, Taipei, Taiwan. *Pharmacoepi Drug Saf* 2014;23(S1):85-86.

Poster and Oral Presentations (P=poster)

1. **Delaney JA**. Latent semantic indexing. Graduate Student Presentation Day, Lakehead University, March 1997.

2. **Delaney JA**. Informed consent and disease registries: Why consent should not be required. HRQAN Conference. September 22nd, 2004, Montreal, Quebec, Canada.

3P. Dial S, **Delaney JA**, Barkun A and Suissa S. Proton pump inhibitors and the risk of community-acquired *clostridium difficile* disease. Réseau québécois de la recherche sur l'usage des médicaments (RQRUM). May 26th, 2005, Montreal, Quebec, Canada.

4. **Delaney JA** and Suissa S. Warfarin use and the risk of injurious motor vehicle accidents. 2005 McGill Epidemiology, Biostatistics and Occupational Health Student Research Day. June 13th, 2005, Montreal, Quebec, Canada.

5. **Delaney JA** and Suissa S. Warfarin use and the risk of motor vehicle crashes in the elderly. GEIRO First International Conference. Pharmaceutical Drugs. September 1st, 2005. Montreal, Quebec, Canada.

6. Wilchesky M, **Delaney JA**, McDonald S, Platt RW, Dial S and Suissa S. The causal effect of prescription drugs on community – acquired *Clostridium difficile* associated disease: A marginal structural models analysis. Health Outcomes Research Day, MUHC, Montreal, Canada, May 24th, 2006.

7P. **Delaney JA**, Wilchesky M, McDonald S, Platt RW, Dial S and Suissa S. Model selection techniques in probability of treatment models: An application to marginal structural models. Health Outcomes Research Day, May 24th, 2006, Montreal, Quebec, Canada.

8. **Delaney JA**, Dial S, Barkun AN and Suissa S. Residual effects of proton pump inhibitors on the risk of community acquired *clostridium difficile*. 23rd International Biometrics Conference, July 20th, 2006. Montreal, Quebec Canada.

9P. **Delaney JA**, Brophy JM, Steele RJ, Opatrny L and Suissa S. Multiple Imputation for Blood Pressure in the General Practice Research Database. Third Annual McGill Epidemiology, Biostatistics and Occupational Health Research Day. May 1st, 2007, Montreal, Quebec, Canada.

10. Blagojevic A, Dendukuri N, **Delaney JAC**, Boivin JF and Brophy JM. An interaction between statins and clopidogrel – A cohort study with survival time analysis. 3rd Annual Epidemiology, Biostatistics and Occupational Health Research Day, May 1st, 2007, Montreal, Quebec, Canada
11. Daskalopoulou SS, **Delaney JAC**, Filion KB, Brophy JM, Mayo NE and Suissa S. Reverse Protopathic Bias or Biological Rebound: A Study of Post-Myocardial Infarction Statin prescribing. 3rd Annual Epidemiology, Biostatistics and Occupational Health Research Day, May 1st, 2007, Montreal, Quebec, Canada.
12. Ionescu-Ittu R, **Delaney JA** and Abrahamowicz M. Assessing the Use of Physician's Prescription Preference as an Instrumental Variable to Reduce the Impact of Unobserved Confounding in Pharmacoepidemiologic Studies. 3rd Annual Epidemiology, Biostatistics and Occupational Health Research Day, May 1st, 2007, Montreal, Quebec, Canada.
13. Schneider-Lindner V, **Delaney JA** and Suissa S. When do they start? The unexposed in infectious disease prognostic studies. 3rd Annual Epidemiology, Biostatistics and Occupational Health Research Day, May 1st, 2007, Montreal, Quebec, Canada.
14. Daskalopoulou SS, **Delaney JAC**, Filion KB, Brophy JM, Mayo NE and Suissa S. Discontinuing Statins After an Acute Myocardial Infarction. What are the Consequences? 6th Annual Research Day - Health Outcomes Axis - MUHC Research Institute. May 24th 2007 McGill University. Montreal, Quebec, Canada.
- 16P. Dial S, **Delaney C**, Baldry C and Benedetti A. The Risk of C. difficile Associated Disease in Patients Exposed to Prophylactic Antibiotics only during a CDAD Outbreak. ASM (American Society for Microbiology) 107th General Meeting May 25th 2007. Toronto, Ontario, Canada.
17. Ionescu-Ittu R, **Delaney JA** and Abrahamowicz MA. Assessing the Efficiency of using Physician's Prescription Preferences as an Instrumental Variable to Reduce the Impact of Unobserved Confounding in Pharmacoepidemiologic Studies. 28th Annual Conference International Society for Clinical Biostatistics, July 30th, 2007, Alexandroupolis, Greece.
18. Grunfeld C, Delaney JAC, Wanke C, Currier J, Scherzer R, Biggs ML, Sidney S, Polak J, O'Leary D and Kronmal R. HIV infection is independently associated with great atherosclerosis measured by Carotid IMT Similar in Magnitude to that of traditional CVD Risk factors. 16th Conference on Retroviruses and Opportunistic Infections, February, 2009, Montreal, Canada.
19. Crane, HM, Paramsothy, P, Heckbert, SR, Budoff, MJ, Delaney, JAC, Lober, WB, Willig, JH, Mugavero, MJ, Mathews, WC, Rodriguez, C, Moore, RD, Eron, JJ, Napravnik, S, Grunfeld, C, Saag, MS, Kitahata, MM, for the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) Cohort. Secondary myocardial infarctions (MIs) are common among patients with HIV and associated with lower prior predicted 10-year cardiovascular disease risk than primary events. 16th International Workshop on HIV Observational Databases
20. Danijela Stojanovic, Jonathan Schelfhout, Amy Houtchens, Heidi M Crane, Elizabeth Brown, Nina Kim, Mari M Kitahata, Teresa L Kauf, **Joseph AC Delaney**. Changes in Platelet Counts over Time in HIV and Hepatitis C Virus (HCV) Co-infected Patients. ICPE Annual Meeting, Barcelona, Spain, Aug 2012.

21. Monica A Munoz, Danijela Stojanovic, Mahyar Etminan, Almut G Winterstein, **Joseph AC Delaney**. Trends in use of benzodiazepines, opioids, tramadol, and z-drugs from 1998 to 2008 in a managed care population. ICPE Annual Meeting, Barcelona, Spain, Aug 2012.

22. David B. Hanna, Robert C. Kaplan, Mengye Guo, Petra Bůžková, Tracie L. Miller, Wendy S. Post, James H. Stein, Judith S. Currier, Richard A. Kronmal, Matthew S. Freiberg, Siiri N. Bennett, Cecilia M. Shikuma, Kathryn Anastos, Russell P. Tracy, Howard N. Hodis, **Joseph A. Delaney**. HIV infection and carotid artery intima-media thickness: Pooled analyses across five cohorts of the NHLBI HIV-CVD Collaborative. 19th International Workshop on HIV Observational Databases, March 26-28, 2015.

Informal Lectures

1. Designing bootstrap models in SAS. Presented: Department of Epidemiology and Biostatistics, McGill University, March 2003.

2. Warfarin use and the risk of injurious motor vehicle accidents – a study of bias. Presented: Department of Epidemiology and Biostatistics, McGill University, September 2003.

3. Debater “Informed consent: Help or Hindrance?”, 7th Annual Symposium: Research & Quality of Care, St. Mary’s Hospital, Montreal, Quebec Canada, November 2006

Session Chair at Conference

Student Skills Workshop. International Conference on Pharmacoepidemiology. Quebec City, Quebec, Canada. August 19th, 2007.

Database Development session. International Conference on Pharmacoepidemiology: Mid-Year Session. Miami, Florida. April 23rd, 2012.

12. University Service

Tuition Committee, School of Public Health, University of Washington (2013-2014)

Scholarship and Awards committee, College of Pharmacy, University of Florida (2011-2012)

Coordinator, Works in Progress seminar series, Collaborative Health Studies Coordinating Center (2009)

Coordinator, Causal Inference Reading Group, Department of Epidemiology, Biostatistics and Occupational Health, McGill University (2006)

Coordinator, Pharmacoepidemiology Journal Club, Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University Health Centre (2003-2006)

VP Finance, EBSS, McGill University (2005-2006)

Student Representative, PhD Comprehensive Examinations Committee, Department of Epidemiology and Biostatistics, McGill University (2003-2006)

Organizer, McGill Epidemiology, Biostatistics and Occupational Health Research Day (2004-2007)

Student Representative, PhD Program Committee, Department of Epidemiology and Biostatistics, McGill University (2003-2005)

Vice President, EBSS (2004-05)

Secretary, Epidemiology and Biostatistics Student Society (EBSS), Department of Epidemiology and Biostatistics, McGill University (2002-2003)

President, Lakehead University Philosophy Association, Lakehead University (1992-1993)

Treasurer, Lakehead University Philosophy Association, Lakehead University (1991-1992)

13. Professionally-Related Community Service

N/A

14. Citizenship

Canadian Citizen
US permanent resident

15. Teaching History

Co-Instructor: Epidemiology 510. University of Washington. Co-taught with Rachel Winer. Two sections. 2016.

Instructor: Epidemiology 528 (Exposure Measurement). University of Washington. 2015.

Guest Lecturer (Epi 519: Cardiovascular Epidemiology), 2 hours, University of Washington, 2014

Guest Lecturer (Epi 533: Pharmacoepidemiology), 2 hours, University of Washington, 2014

Co-Instructor: Epidemiology 528 (Exposure Measurement). University of Washington. Co-taught (with Emily White) 2013-2014.

Instructor: Advanced Pharmacoepidemiology Course (Marginal Structural Models section). ICPE conference short course (part of Advanced Pharmacoepidemiology). August 2011.

Instructor (Pharmacy 6935: Advanced Pharmacoepidemiology). Full one semester course (developed and taught), University of Florida, 2010/11, 2011/12.

Instructor (Pharmacy 6805: Data Analysis and Interpretation). Full one semester course (developed and taught), University of Florida, 2010/11, 2011/12.

Guest Lecturer (Pharmacoepidemiology), 2 hours, University of British Columbia, 2008

Guest Lecturer (Advanced Pharmacoepidemiology), 6 hours, McGill University, 2006-2007

Teaching Assistant (Clinical Epidemiology), McGill University, 2006

Teaching Assistant (Physics) University of Waterloo, 1997-1998

Teaching Assistant (Mathematics and Statistics) Lakehead University, 1995-1997

Teaching Assistant (Physics) University of Western Ontario, 1993-1995

16. Advising and Formal Mentoring

a) PhD Dissertations, chair

Florida

Danijela Stojanovic* (PhD, Pharmaceutical Outcomes and Policy) 09/2010 to 04/2015 (graduated)

*DS is co-chaired with W. Thomas Smith as lead

Washington

Jessica Williams-Nguyen (PhD, Epidemiology) ongoing

b) Masters Theses, chair

Florida

Monica Munoz (MSc, Pharmaceutical Outcomes and Policy) 09/2010 to 04/2012 (graduated)

Salvatore Pepe (MSc, Pharmaceutical Outcomes and Policy) 09/2010 to 04/2012 (graduated)

Washington

Emily Kurlak (MS, Nutrition) ongoing

Lauren N Strand (MS, Epidemiology) ongoing

Anna E Eney (MS, Nutrition) ongoing

c) Mentored Scientists and Postdocs

d) MS and PhD committees in non-chair role

Florida

Jennifer Guo (PhD Pharmacy) Graduated

Steve Bird (PhD. Pharmacy) Graduated

Efe Eworuke (PhD, Pharmacy) Graduated

Lily Ma (PhD, Pharmacy) Graduated

Wei Liu (PhD, Pharmacy) Graduated

Washington

Robin Nance (MS, Biostatistics) Graduated

Dan Drozd (MS, Epidemiology) Graduated

Andrew Spieker (PhD, Biostatistics) Ongoing

GSR at University of Washington

Nathanial E Watson (PhD, Chemistry) Ongoing

e) Other Mentoring (Undergraduate Research, Medical School ISMS Projects, etc.)

f) Academic Advising